At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled / 22 target
Drug / intervention
Amino-acid PETother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Amino Acid PET Imaging to Assess the Efficacy of IDH Inhibitor Treatments for Patients With Refractory IDH Mutated Gliomas
In Brief
An observational study evaluating Amino-acid PET for Glioma. Completed, enrolled 22 participants across 1 site.
Signals
Enrolling ahead of pace
Detailed Summary
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2026
First PostedJun 2025
Enrollment StartJun 2025
Primary CompletionJul 2025
Study CompletionAug 2025
TodayJul 2026
First PostedJun 12, 2025
Enrollment StartJun 30, 2025
Primary CompletionJul 1, 2025
Study CompletionAug 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1 daysPosted 1.1 years ago
Interventions
Amino-acid PETother
Patients received 18-fluoroDopa then a PET exam